Bolt Biotherapeutics Inc [BOLT] stock prices are down -2.95% to $0.57 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BOLT shares have gain 5.63% over the last week, with a monthly amount drifted -3.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
The stock price of Bolt Biotherapeutics Inc [BOLT] has been fluctuating between $0.47 and $1.56 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $0.57 at the most recent close of the market. An investor can expect a potential return of 75.44% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
The Bolt Biotherapeutics Inc [NASDAQ:BOLT] reported sales of 9.78M for trailing twelve months, representing a drop of -54.87%. Gross Profit Margin for this corporation currently stands at -0.68% with Operating Profit Margin at -7.76%, Pretax Profit Margin comes in at -6.66%, and Net Profit Margin reading is -6.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.83. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5368 points at the first support level, and at 0.5084 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6068, and for the 2nd resistance point, it is at 0.6484.
Ratios To Look Out For
It’s worth pointing out that Bolt Biotherapeutics Inc [NASDAQ:BOLT]’s Current Ratio is 3.16. As well, the Quick Ratio is 3.16, while the Cash Ratio is 0.52. Considering the valuation of this stock, the price to sales ratio is 2.21, the price to book ratio is 0.30.
